



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE: 044-25267517/25270992/42677555, FAX: 91-44-25231264, email: info@bafnapharma.com, Website, www.bafnapharma.com
CIN : L24294 TN1995PLC030698

Date: 13th Aug 2018

Listing Department BSE Limited P J Towers Dalal Street, Mumbai – 400 001	Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400051
Security code : 532989 Security ID : BAFNAPHARM	Symbol : BAFNAPHARM Series : EQ

Dear Sir,

Sub.- outcome of the board meeting held on 13th Aug 2018

We would like to inform you that the Board at its meeting held on today approved the un-audited financial results for the quarter ending 30th June 2018. Please find attached the un-audited financial results for the first quarter ending 30th June 2018 along with the Limited Review Report obtained from the statutory auditor of the Company.

The meeting commenced at 7.30 PM and concluded at 8.30 PM

Kindly take it on record.

Thanking you

Yours faithfully,
For BAFNA PHARMACEUTICALS LIMITED

Jitendra Kumar Pal
Company Secretary

BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter Ended 30 th June 2018

PART I		(Rs. In Lakhs) except EPS			
Sl.No	Particulars	3 months ended	Preceding	Corresponding 3	For the Previous
		(30-06-2018)	3 months ended	months ended	Year ended
		Unaudited	Audited	Unaudited	Audited
I	Revenue From operations	1,195.13	1,652.27	910.38	4,717.07
II	Other Income	9.19	93.49	7.23	122.80
II(a)	Profit on sale of Investment	-	-	-	3,003.64
III	Total income (I+II)	1,204.31	1,745.76	917.61	7,843.51
IV	EXPENSES				
a)	Cost of materials consumed	1,093.80	1,290.93	601.54	2,680.07
b)	Purchases of Stock-in-Trade	15.00	600.44	-	1,298.95
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	(5.08)	(44.44)	393.60	409.20
d)	Employee benefits expense	194.31	228.50	158.38	747.49
e)	Finance costs	83.21	102.20	187.49	680.53
f)	Depreciation and amortization expenses	100.00	76.69	92.79	364.59
g)	Other expenses	78.56	2,861.38	64.81	3,090.24
	Total expenses (IV)	1,559.81	5,115.69	1,508.61	9,271.08
V	Profit/(loss) before exceptional items and tax (I-IV)	(355.50)	(3,369.93)	(591.00)	(1,427.56)
VI	Exceptional Items				
VII	Profit/ (loss) before exceptions Items and tax(V-VI)	(355.50)	(3,369.93)	(591.00)	(1,427.56)
VIII	Tax expense:				
	(1) Current tax	-	-	-	-
	(2) Deferred tax	(4.19)	46.80	169.66	217.52
IX	Profit (Loss) for the period from continuing operations (VII-VIII)	(351.31)	(3,416.72)	(760.66)	(1,645.09)
X	Profit/(loss) from discontinued operations	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(351.31)	(3,416.72)	(760.66)	(1,645.09)
XIV	Other Comprehensive Income				
	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	(351.31)	(3,416.72)	(760.66)	(1,645.09)
XVI	Earnings per equity share (for continuing operation):				
	(1) Basic	(1.49)	(14.44)	(4.08)	(6.95)
	(2) Diluted	(1.49)	(14.44)	(4.08)	(6.95)
XVII	Earnings per equity share (for discontinued operation):				
	(1) Basic	-	-	-	-
	(2) Diluted	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)				
	(1) Basic	(1.49)	(14.44)	(4.08)	(6.95)
	(2) Diluted	(1.49)	(14.44)	(4.08)	(6.95)

1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 13.08.2018

2. Status of Investor Complaints;

I	Opening balance	NIL
II	Pending at the beginning of the quarter	NIL
III	No. of complaints received and disposed off during the quarter	NIL
IV	Complaints pending at the end of the quarter	NIL


3. The Company operates only in one segment, i.e. Pharmaceutical formulations, as such reporting is done on a single segment basis.

4. The above figures have been regrouped and Re-arranged Wherever considered necessary


5. Being the First Quarter of the year, Figures of the Quarter ended 30th June 2018 and Year to date for this Quarter are same hence not mentioned separately

For BAFNA PHARMACEUTICALS

Place: Chennai
Date: 13.08.2018


(BAFNA MAHAVEER CHANDU)
MANAGING DIRECTOR
DIN:01458211

INTERIM RESOLUTION PROFESSIONAL
M/s. BAFNA PHARMACEUTICALS LIMITED


GOPALASAMY GANESH BABU
IBBI/IPA-002/IP-N-00246/2017-18/10731



R. SATHYANARAYANAN & Co.
CHARTERED ACCOUNTANTS

Ph.: 28112450 / 42132674
E-mail:rsathyas@gmail.com

Partners:

CA R. SATHYANARAYANAN, B.Com., F.C.A., ISA
CA R. SATHYANARAYAN, B.Com., F.C.A., ISA.

2 (Old # 21), Ground Floor,
Lakshmipuram 2nd Street,
Royapettah, Chennai - 600 014.

Limited Review Report for the Quarter Ending 30.06.2018

To
The Board of Directors
M/s. Bafna Pharmaceuticals Limited
No.299, Thambu Chetty Street
Chennai - 600001

We have reviewed the accompanying statement of unaudited financial results of M/s. Bafna Pharmaceuticals Limited for the Quarter ended 30 June 2018 (the statement) attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (LODR) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai

Date : 13th August 2018

For R. SATHYANARAYANAN & CO.
Chartered Accountants
(ICAI Regd. No. 028377)
Partner
R. Sathyanarayanan
M. No. 028377

R. SATHYANARAYANAN & CO.,
Chartered Accountants
No.2, (Old No.21), Ground Floor,